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Abstract
Background: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is now the most common cause
of skin and skin structure infections (SSSI) in several world regions. In Argentina prospective, multicenter clinical studies
have only been conducted in pediatric populations.
Objective: Primary: describe the prevalence, clinical and demographic characteristics of adult patients with community
acquired SSSI due to MRSA; secondary: molecular evaluation of CA-MRSA strains. Patients with MRSA were compared to
those without MRSA.
Materials and Methods: Prospective, observational, multicenter, epidemiologic study, with molecular analysis, conducted at
19 sites in Argentina (18 in Buenos Aires) between March 2010 and October 2011. Patients were included if they were $14
years, were diagnosed with SSSI, a culture was obtained, and there had no significant healthcare contact identified. A
logistic regression model was used to identify factors associated with CA-MRSA. Pulse field types, SCCmec, and PVL status
were also determined.
Results: A total of 311 patients were included. CA-MRSA was isolated in 70% (218/311) of patients. Clinical variables
independently associated with CA-MRSA were: presence of purulent lesion (OR 3.29; 95%CI 1.67, 6.49) and age ,50 years
(OR 2.39; 95%CI 1.22, 4.70). The vast majority of CA-MRSA strains causing SSSI carried PVL genes (95%) and were SCCmec
type IV. The sequence type CA-MRSA ST30 spa t019 was the predominant clone.
Conclusions: CA-MRSA is now the most common cause of SSSI in our adult patients without healthcare contact. ST30,
SCCmec IV, PVL+, spa t019 is the predominant clone in Buenos Aires, Argentina.
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Introduction
Community-associated methicillin-resistant Staphylococcus aureus
(CA-MRSA) has emerged in different world regions [1] including
Latin America [2,3] as a major cause of acute bacterial skin and
skin structure infections (SSSI). Different from hospital-acquired
MRSA, CA-MRSA usually is mec type IV, carries genes for
Panton-Valentine leukocidin (PVL) and is susceptible to several
non ß-lactam antibiotics [4].
In Argentina prospective, multicenter, studies with molecular
evaluation of community MRSA in patients with SSSI have only
been conducted in pediatric populations [5,6]. However, despite
the observation that the clinical characteristics of SSSI in adults
appear similar to those of children the prevalence of CA-MRSA in
adolescents and adults presenting with SSSI infection have not
been determined.
The epidemic of CA-MRSA is evolving [7]. A specific clone
that is initially propagating and causing CA-MRSA infections can
be displaced by a more successfully one. For example in the US
the initially reported CA-MRSA clone USA 400 was subsequently
replaced by the USA 300 which became the most common cause
of SSSI [1,8]. In Argentina previous studies have identified ST5,
SCCmec IV, spa type 311 as the predominant CA-MRSA clone
causing infections [6] and colonizing children [9]. Microbiolog-
ically based studies have suggested the same clonal predominance
of CA-MRSA among Argentinean adults [10]. Whether this clone
of CA-MRSA is still dominant or has been replaced in adult
patient with SSSI in our country needs to be determined. The
current study was conducted to establish the prevalence, clinical
and molecular characteristics of CA-MRSA in adolescents and
adults with SSSI in Argentina.
Materials and Methods
A prospective, observational, multicenter study was conducted
in a total 19 centers (18 in Buenos Aires state and city, and 1 in
Santa Fe state) between March 2010 and October 2011. The
primary objective was to determine prevalence, clinical and
demographic characteristics in patients with SSSI due to CA-
MRSA. Secondary objective was to perform a molecular analysis
of CA-MRSA strains.
Patients were included if they had$14 years old, presented with
SSSI and had a culture obtained. Patients were excluded if they
had any of the following contacts with the healthcare system
within the last 12 months: hospitalization, chronic care (e.g.
nursing home), catheter placement, dialysis or surgery.
The information was collected using an electronic clinical report
form (eCRF). Patients were followed for at least one visit after the
end of antimicrobial therapy. Clinical outcomes were defined as
follows: a) cure, resolution of signs and symptoms of infection to the
point at which no further antibiotics or procedures were deemed
necessary, b) failure, need for a different antibiotic based on lack of
clinical response, worsening of signs or symptoms, and/or need for
an additional surgical procedure after end of therapy, and c)
indeterminate, unable to assess clinical outcome (e.g. missing follow
up). Clinical outcomes of cure and failure were captured during
medical visits conducted for regular care (not a fixed time point).
Predisposing factors for SSSI and CA-MRSA infections were
selected from the literature. Data was analyzed utilizing SAS 9.3
(Cary, North Carolina). Patients with CA-MRSA were compared
to those without CA-MRSA (culture negative or pathogens other
than CA-MRSA) using Chi square or Fisher’s exact test
(categorical variables) and t-test or Wilcoxon rank sum (continous
variables), as appropriate. A logistic regression model (backward
stepwise) was conducted to identify clinical variables associated
with CA-MRSA infection. Clinically relevant variables with p
values p#0,05 in the univariate analysis were included in the
model. The information of the study was kept confidential until the
database was anonymized.
Pathogen identification and antibiotic susceptibility was ob-
tained from each institutional microbiology laboratory. MRSA
isolates were sent to a reference laboratory (Ca´tedra de
Microbiologı´a, Facultad de Farmacia y Bioquı´mica, Universidad
de Buenos Aires). Resistance to methicillin was confirmed through
PCR amplification of mecA gene. S. aureus ATCC strains 43300
and 29213 were used as positive and negative controls, respec-
tively. SCCmec types were identified analyzing mec and ccr elements
[11]. Presence Panton-Valentine leucocidin (PVL) genes (lukS/F-
PV) were also determined [12].
Pulse field gel electrophoresis (PFGE) was performed as
described by Chung [13]. PFGE also included locally circulating
clones (e.g. clone CAA, pulse field type A, ST5, spat311,
SCCmecIV, PVL+) and one strain characterized as pulse field
type C, ST30, spat019, SCCmecIV, PVL+ [14]. The analysis of
PGFE profiles was carried out by visual inspection. A dendrogram
(Treecon 1.3b) was built applying unweighted pair-group method
clustering analysis (UPGMA) algorithm and Dice coefficient.
Isolates with similar band pattern ($85%) were considered to
belong to the same pulse field type. Profiles observed were named
according to their similarity to control pulse field types (A and C).
Genotype analysis of isolates was also performed using spa typing
[15]. Data obtained was analyzed using a reference website:
http://www.ridom.de/spaserver (last accessed on November 20th
2012). A representative proportion of isolates from each pulse
fieldtype were studied using multi locus sequence typing (MLST)
(http://saureus.mlst.net/; last accessed on November 20th 2012)
The study was approved by Institutional Review Boards (IRB)
from participating institutions. In all cases the adult participants
gave written or verbal consent as required by the IRBs. In accord
with local IRB instructions the following participating sites
required written informed consent (ICF): Hospital Dr. Jose` Marı´a
Cullen, Hospital Espan˜ol de Buenos Aires, Hospital Bernardo
Houssay de Vicente Lo´pez, Htal. F. Santojanni, Policlı´nico
Central de La Matanza (for patients ,18 years old) and Sanatorio
Otamendi. At the above sites written informed consent forms for
patients ,18 years old were obtained from parents or legal
guardians on the behalf of the participant minors/children. Given
the observational nature of the study and the anonymization of
data the remaining IRBs from participating institutions did not
required written ICF (regardless of patient’s age). The IRBs from
the following participating sites approved the study and required
only verbal consent without need of documentation: Centro de
Educacio´n Me´dica e Investigaciones Clı´nicas (CEMIC), Htal.
Aerona´utico Central, Htal. Espan˜ol de Buenos Aires, Htal. Evita
Pueblo, Htal. Juan A. Ferna´ndez, IPER, Htal. Nuestra Sen˜ora de
Luja´n, Htal. Privado de la Comunidad, Htal. Tornu´, Htal.
Universidad Abierta Interamericana, Htal. Velez Sarfield, Htal.
IGA Vicente Lo´pez, Policlı´nico Central de La Matanza (for $18
years old), Sanatorio Municipal Dr. Julio Me´ndez, Sanatorio
Tandil. The verbal consent for patients ,18 years old were
obtained from parents or legal guardians on the behalf of the
minors/children participants. There was no need for IRB
approval at Hospital Brita´nico de Buenos Aires (study previously
discussed with the site IRB and in compliance with their policies
for observational studies with anonymized data; verbal waiver
obtained from the IRB board members).
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Results
A total of 311 patients were enrolled during the study period in
19 centers. The majority of patients were male (60%) and the
mean age was 38,8 (618,1) years old (Table 1). A history of
previous furuncles was the most predisposing factor for SSSI
(36%). Almost 70% of patients had an identifiable predisposing
factor for CA-MRSA. Among such factors the receipt of
antibiotics within the last 12 months was the most common.
Abscesses and furuncles were the most frequent SSSIs account-
ing for 70% of the cases. A vast majority of patients had purulent
lesions and one third presented with fever. Almost 90% (271/
311) of patients had positive cultures. Among subjects with
positive cultures C-MRSA was obtained in 80,4% followed by
Table 1. Clinical and demographic characteristics in patients with skin and skin structure infections due to community-associated
MRSA.
Variables
Total N=311
n/N (%)
CA- MRSA N=218
n/N (%)
No MRSA N=93
n/N (%) p*
Demographic
characterstics
Gender male 187/311 (60,1%) 133/218 (61%) 54/93 (58,1%) 0,63
Age in years, mean (6SD) 38,8 (618,1) 36,1 (616,7) 45,3 (619,7) 0,0001
,50 years old 225/307(73,6%) 172/215 (80,0%) 53/92 (57,6%) ,0,0001
BMI, mean (6 SD) 26,5 (65,7) 25,8 (65,1) 28,2 (66,6) 0,006
BMI#25 107/239 (44,8%) 82/166 (49,4%) 25/73 (34,2%) 0,03
Predisposing factors
for skin infections
Total{ 232/311 (74,6%) 160/218 (73,4%) 72/93 (77,4%) –
Furunculosis (history) 113/311 (36,3%) 93/218 (42,7%) 20/93 (21,5%) 0,0004
Trauma 44/311 (14,2%) 29/218 (13,3%) 15/93 (16,1%) 0,51
Diabetes 37/311 (11,2%) 23/218 (10,6%) 14/93 (15,1%) 0,26
HIV 24/311 (7,7%) 20/218 (9,2%) 4/93 (4,3%) 0,14
Peripheral vascular disease 22/311 (7,1%) 12/218 (5,5%) 10/93 (10,8%) 0,1
Immunosuppressant therapy 22/311 (7,1%) 11/218 (5,1%) 11/93 (11,8%) 0,03
Predisposing factors
for CA-MRSA
Total 217/311 (69,8%) 167/218 (73,6%) 50/93 (53,8%) –
Previous antibiotics last 12 months 152/311 (48,9%) 117/218 (53,7%) 35/93 (37,6%) 0,01
Previous antibiotics last 30 days 121/311 (38,9%) 90/218 (41,3%) 31/93 (33,3%) 0,19
House contacts with similar lesions 78/311 (25,1%) 64/218 (29,4%) 14/93 (15,1%) 0,008
Contact sports 49/311 (15,8%) 37/218 (17,0%) 12/93 (12,9%) 0,37
Nasal swab, MRSA
positive`
15/65 (23,1%) 15/50 (30,0%) 0/15 (0%) 0,01
Type of lesion ,0,0001
Furuncle 111/311 (35,7%) 88/218 (40,4%) 23/93 (24,7%) –
Abscess 107/311 (34,4%) 91/218 (41,7%) 16/93 (17,2%) –
Celullitis 77/311 (24,8%) 33/218 (15,1%) 44/93 (47,3%) –
Ulcer 9/311 (2,9%) 5/218 (2,3%) 4/93 (4,3%) –
Fasciitis 4/311 (1,3%) 0/218 (%) 4/93 (4,3%) –
Erisypela 2/311 (0,6%) 0/218 (0%) 2/93 (2,2%) –
Burn 1/311 (0,3%) 1/218 (0,5%) 0/93 (0%) –
Clinical characteristics Fever 102/311 (32,8%) 70/218 (32,1%) 32/93 (34,4%) 0,69
Skin lesion multiple 93/311 (29,9%) 77/218 (35,3%) 16/93 (17,2%) 0,001
Skin lesion purulent 236/311 (75,9%) 184/218 (84,4%) 52/93 (55,9%) ,0,0001
Skin lesion necrotic 26/311 (8,4%) 13/218 (6,0%) 13/93 (13,4%) 0,02
WBC.106109/L 78/126 (61,9%) 53/84 (63,1%) 25/42 (59,5%) 0,70
Antibiotics within the last 72 hours 145/311 (46,7%) 104/218 (47,7%) 41/93 (44,1%) 0,56
MRSA denotes methicillin-resistant Staphylococcus aureus; CA-MRSA denotes community-associated MRSA; BMI, body mass index.
Data are displayed with n/N (%), except for continuous variables which are expressed by mean or median (standard deviation or interquartile range).
Predisposing factors for skin infections as well predisposing factors for Community MRSA displayed in this table were selected from medical literature. Comparisons
were exploratory.
*Comparing patients with community-associated MRSA vs. those without community-associated MRSA.
{Including furunculosis as a predisposing factor.
`From the total of patients with nasal swabs.
doi:10.1371/journal.pone.0078303.t001
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methicillin-susceptible S. aureus (MSSA) which was isolated in
11,1% of patients, respectively(Table 2).
Patients infected with CA-MRSA (compared to those without
CA-MRSA) were younger (36,1 vs. 45,3 years old; p = 0,0001) and
had lower body mass index (BMI) (25,8 vs. 28,2; p = 0,006).
Patients with C-MRSA more frequently gave a history of furuncles
(42,7% vs. 21,5%; p = 0.0004), contacts with persons exhibiting
similar skin lesions (29,4% vs. 15,1%; p = 0,008), and purulent
(84% vs. 56%; p =,0.0001) or multiple lesions (35% vs. 17%;
p = 0.005) (Table 1). Patients infected with CA-MRSA were more
commonly found to have abscesses (41,7% vs. 17,2%) or furuncles
(40,4% vs. 24,7%) and less frequently were diagnosed with
cellulitis (15,1% vs. 47,3%) than patients without CA-MRSA
(p,0,0001). Necrotic lesions were less common in patients with
CA-MRSA (6% vs. 13,4%; p = 0,02).
All CA-MRSA strains tested were susceptible to minocycline
and more than 95% were susceptible to trimethoprim-sulfameth-
oxazole and rifampin. Resistance to clindamycin was detected in
11% and resistance to $2 non ß-lactam antibiotics was present in
12% of community MRSA strains, respectively. From the 146
MRSA isolates analyzed in the central laboratory methicillin
resistance was confirmed in all and PVL genes were present in
94.5% of strains. SCCmec type IV was detected in 93.1% (136/
146) of CA-MRSA isolates and only one strain had SCCmec type
V. The predominant clone of CA-MRSA in patients with SSTI
was characterized as pulse field type C, sequence type 30 (ST-30),
spa t-019 (Table 3). The most common PFGE types identified are
displayed in Figure 1.
Approximately half of study patients received prior antibiotic
therapy for their SSSIs (Table 4). The most commonly used prior
antibiotics were first generation cephalosporins followed by
amoxicillin-clavulanate. Prior antibiotic therapy was more com-
mon among patients infected with CA-MRSA than in those
without CA-MRSA (58,3% vs. 43%; p = 0,01). Prior antibiotic
therapy received in the majority of patients with CA-MRSA was
deemed to be inadequate based on in vitro susceptibilities (78%).
Almost all patients with prior therapy (with or without CA-MRSA)
required continued antibiotic therapy after the first study visit and
in 82% of cases such therapy was adjusted to a different antibiotic.
The most frequently used antibiotics after the first study visit were
trimethoprim-sulfamethoxazole and clindamycin. Antibiotic ther-
apy had a median duration of 10 days. Slightly more than half of
the patients underwent drainage at the beginning of the study.
There were no differences between patients infected with CA-
MRSA and those who were not infected with CA-MRSA in terms
of number, type of drainage (surgical vs. non-surgical) or length of
antibiotic treatment. Patients with CA-MRSA (compared to those
without CA-MRSA) were more commonly changed antibiotic
therapy after the first study visit based on culture results (23,9% vs.
12,9%; p = 0.03).
Patients infected with CA-MRSA were less commonly admitted
to hospital than those without CA-MRSA (33,5% vs. 50,5%;
p = 0,005). Overall cure rates were above 85%. There was no
difference in cure rates between patients with CA-MRSA and
those without CA-MRSA (Table 5). In the multivariable analysis
two factors were independently associated with CA-MRSA in
patients with SSSIs: presence of purulent lesions (OR 3,29; 95%
Table 2. Microbiological results and MRSA susceptibilities in patients with skin and skin structure infections.
Variables n/N (%)
Positive culture Total 271/311 (87,1%)
Monomicrobial 267/271 (98,5%)
Most frequent pathogens* MRSA 218/271 (80,4%)
MSSA 30/271 (11,1%)
Coagulase negative staphylococci 5/271 (1,8%)
S.pyogenes 3/271 (1,1%)
S. viridans 4/271 (1,5%)
Streptococcus group B, C, G 5/271 (1,8%)
P. aeruginosa 3/271 (1,1%)
Other 7/271 (2,6%)
Culture of primary skin lesion 311/311 (100%)
Type of culture{ Needle aspiration 265/311 (85,2%)
Surgical sample 55/311 (17,7%)
MRSA susceptibilities` Minocycline 141/141 (100%)
Rifampin 184/186 (98,9%)
TMP-SMX 207/210 (98,6%)
Quinolones 175/185 (94,6%)
Aminoglycosides 153/166 (92,2%)
Clindamycin 188/211 (89,1%)
Macrolides 172/200 (86,0%)
MRSA denotes methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; TMP-SMX, trimethoprim-sulphametoxazole.
*From the total of patients with positive cultures; 275 pathogens were isolated from 271 patients; 4 patients had two pathogens isolated, respectively; other pathogens
include Proteus mirabilis (n = 2), Citrobacter spp (n = 2), Acinetobacter spp (n = 1), E.coli (n = 1), E. faecalis (n = 1).
{A single patient may have more than one type of culture.
`From the total of isolates tested; susceptibilities were determined at each microbiology laboratory following their standards.
doi:10.1371/journal.pone.0078303.t002
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confidence intervals 1.67, 6.49) and age ,50 years old (OR 2,39;
95% confidence intervals 1.22, 4.70) (model c-index 0,75)
(Table 6).
Discussion
This prospective, multicenter study of CA-MRSA strains in
adolescent and adult patients with SSSI in Argentina provided
several findings.
Firstly, CA-MRSA has become the most common cause of skin
and soft tissue infections in our patient without healthcare contact.
From the total of 311 patients enrolled with SSTI 70% had CA-
MRSA. The high rates of CA-MRSA observed among our
patients with SSSI were similar to the rates observed in certain
regions of the US [1,8,16]. This finding confirms our individual
observations and will have significant impact on our antibiotic
choices in the treatment of such patients. The occurrence of CA-
MRSA as the predominant pathogen prompts an urgent change in
the empirical therapy used to treat our community patients with
SSSI. In addition, results from this study should encourage
physicians to obtain cultures in patients with SSSI, most
importantly in those areas where the prevalence of CA-MRSA
or its antibiotic susceptibility are unknown [17].
Second, , this study reveals the predominance of the clone ST-
30 SCCmec IV, PVL+ spa t019 among our patients from the
community. This clone which was previously considered as an
uncommon clone in Argentina appears to have displaced the
previously predominant clone (ST5, SCCmec IV, PVL+) [6,14].
Consistent with this finding we have recently described predom-
inance of ST-30 SCCmec IV, PVL+ spa t019 among patients with
invasive CA-MRSA infections in Argentina [18]. Predominance of
one clone over the others could be associated with fitness
advantages and reflects the dynamism of CA-MRSA epidemic
[7,19,20]. Interestingly strains belonging to clonal complex 30
seem to have a different repertoire of enterotoxins, adhesins as well
as important association with infective endocarditis [21]. Although
our study was focused on community patients with SSSI CA-
MRSA is a well known cause of invasive and hospital acquired
infections [22–24] which are also occurring in our country [18,25].
Third, SSSI caused by CA-MRSA have some characteristics
that can be easily detected at the initial clinical evaluation. In our
community population CA-MRSA is more common in patients
,50 years old and presenting with purulent lesion such as
abscesses or furuncles. Although PVL is not a primary determi-
nant of outcome in patients with SSTI caused by CA-MRSA
[26,27] the leucocidin is associated with pus formation [28]. In fact
our multivariable analysis showed that purulent lesions and age
,50 years old were both independently associated with CA-
MRSA. Also the frequent description of contacts with similar
lesions emphases the important finding of a high degree of spread
within closed groups [29,30]. Cure rates were high among our
patients. Importantly, clinical outcomes of patients with SSSI due
to CA-MRSA were not different when compared to the clinical
outcomes of patients without MRSA. These observations are in
agreement with the literature indicating that SSSI due to CA-
MRSA (usually PVL+) have good prognosis, and have similar
outcomes to infections produced by PVL2 MRSA [27] or MSSA
[31].
Our study has several important limitations. Inclusion of
patients may be biased by physicians who included those patients
for whom they suspected CA-MRSA. We believe that the
prospective nature of the study should have attenuated such
potential bias. In fact these high rates of CA-MRSA were
described in other SSSI studies as mentioned before [1,8]. Second,
antibiotic susceptibilities for CA-MRSA were not confirmed in our
reference laboratory. However, susceptibility methods used by
each microbiology laboratory were usually standard for most
determinations. In addition, clinical decisions are based on such
reports making them valuable to the study objectives. We did not
have vancomycin minimum inhibitory concentration values for all
strains. Therefore, we did not report such susceptibility in the
current study. Is still worthy to mention that all isolates were
reported susceptible to vancomycin by the different methods used
Table 3. Molecular characteristics of community-associated MRSA in patients with skin and skin structure infections: pulse
fieldtypes, sequence types, mec and spa types.
PFGE type Isolates (n) ST SCCmec (n) spa type (n)*
A 35 5 IV (35) t311 (14), ND (21)
C 94 30 IV (94) t019 (42), t342(1), t975(2), t021(1), ND (48)
Others 17 ND IV (7), V (1), NT (9) t019 (6), t311 (1), ND (10)
Numbers within parenthesis indicate the number of isolates belonging to each spa type or SCCmec type.
ST denotes sequence type; ND, not determined; NT, non-typeable.
*A representative proportion of isolates from each pulse field type were studied.
doi:10.1371/journal.pone.0078303.t003
Figure 1. Pulse field patterns of representative community
MRSA isolates in patients with skin and skin structure
infections. Lane 1 and 14, pulse field type A clone (CAA); lane 2,
control pulse field type C; lane 5, pulse field type A; lanes 13 and 7 other
pulse field types; lanes 3, 4, 6 and 8–12 pulse field type C.
doi:10.1371/journal.pone.0078303.g001
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Table 4. Most common antibiotic treatments, changes in therapy and drainage in patients with skin and skin structure infections.
Variables
Total N=311
n/N (%)
Community-associated
MRSA N=218
n/N (%)
No Community-associated
MRSA N=93
n/N (%) p*
Prior antibiotic treatment
(before study visits)
Total 167/311 (53,7%) 127/218 (58,3%) 40/93 (43,0%) 0,01
Cephalosporin (1st generation) 98/311 (31,5%) 76/218 (34,9%) 22/93 (23,7%) 0,05
Amoxicillin/clavulanate 35/311 (11,3%) 24/218 (11%) 11/93 (11,8%) 0,83
Trimethoprim-Sulfamethoxazole 17/311 (5,5%) 13/218 (6,0%) 4/93 (4,3%) 0,79
Amoxicillin 13/311 (4,2%) 9/218 (4,1%) 4/93 (4,3%) 1,00
$2 antibiotics 25/311 (8,0%) 18/218 (8,3%) 7/93 (7,5%) 0,83
Actual antibiotic treatment
(at 1st study visit)
Total 309/311 (99,4%) 216/218 (99,1%) 93/93 (100%) 1,00
Different from prior therapy 144/308 (46,8%) 109/217 (50,2%) 35/91 (38,5%) 0,06
Parenteral therapy 87/304 (28,6%) 52/214 (24,3%) 35/90 (38,9%) 0,01
Oral therapy 217/304 (71,4%) 162/214 (75,7%) 55/90 (61,1%) –
Actual antibiotic
treatment, type of agent
(at 1st study visit)
Trimethoprim-Sulfamethoxazole 137/311 (44,1%) 110/218 (50,5%) 27/93 (29,0%) –
Clindamycin 111/311 (35,7%) 78/218 (35,8%) 33/93 (35,5%) –
Cephalosporin (1st generation) 35/311 (11,3%) 13/218 (6,0%) 22/93(23,7%) –
Quinolone 35/311 (11,3%) 24/218 (11,0%) 11/93 (11,8%) –
Rifampin 19/311 (6,1%) 15/218 (6,9%) 4/93 (4,3%) –
$2 antibiotics 79/311 (25,4%) 54/218 (24,8%) 25/93 (26,9%) 0,70
Antibiotic modification
(after 1st visit)
Total 74/311 (23,8%) 58/218 (26,6%) 16/93 (17,2%) 0,07
Based on cultures 64/311 (20,6%) 52/218 (23,9%) 12/93 (12,9%) 0,03
Based on clinical outcomes 27/311 (8,7%) 21/218 (9,6%) 6/93 (6,5%) 0,36
Length of antibiotic
therapy in days, median
(interquartile range)
10 (7, 14) 10 (7, 14) 10 (7, 14) 0,56
Drainage Total 166/311 (53,4%) 123/218 (56,4%) 43/93 (46,2%) 0,1
Surgical drainage 82/311 (26,4%) 57/218 (26,2%) 25/93 (26,9%) 0,89
Non-surgical drainage{ 84/311 (27,0%) 66/218 (30,2%) 18/93 (19,3%) –
MRSA denotes methicillin-resistant Staphylococcus aureus.
*Comparing patients infected with community-associated MRSA vs. those patients without community-associated MRSA.
{It refers to drainage without incision (e.g. needle drainage).
doi:10.1371/journal.pone.0078303.t004
Table 5. Clinical outcomes in patients with skin and skin structure infections.
Clinical outcomes
Total
n/N (%)
Community-associated
MRSA
n/N (%)
No-Community-
associated MRSA
n/N (%) p*
Hospitalization 120/311 (38,6%) 73/218 (33,5%) 47/93 (50,5%) 0,005
Surgical drainage after 1st study consult 58/311 (18,7%) 37/218 (17,0%) 21/93 (22,6%) 0,25
Cure{ 262/301 (87,0%) 184/210 (89,0%) 78/91 (85,7%) 0,65
Failure 8/301 (2,7%) 3/210 (1,4%) 5/91 (5,5%) –
Indeterminate 31/301 (10,3%) 23/210 (11,0%) 8/91 (8,8%) –
Death 5/311 (1,6%) 2/218 (0,9%) 3/93 (3,2%) 0,16
MRSA denotes methicillin-resistant Staphylococcus aureus.
*Comparing patients infected with community-associated MRSA vs. those patients without community-associated MRSA.
{10 patients were excluded because lost of follow up; patients with indeterminate response were included in the denominator.
doi:10.1371/journal.pone.0078303.t005
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(data not shown) at each laboratory. Last, the findings of this study
are mostly limited to Buenos Aires city and state as well as the city
of Santa Fe (Santa Fe state).
Despite the limitations described the current investigation
indicates that CA-MRSA has become the most common cause
of SSSI in our patient population. CA-MRSA is primarily seen in
young adults presenting with purulent lesions and usually responds
well to drainage plus antibacterial therapy. The clone ST30,
SCCmec IV, PVL+, is now the predominant clone in adult patients
suffering from SSSI in Buenos Aires, Argentina.
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